🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Placebo to match IMP TEV-56286, Emrusolmin

    Lacuna Pharma Pty Ltd

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  2. Placebo to match LY, Mirikizumab, Placebo to Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  3. Placebo to match LY3540378

    Eli Lilly Co.

    Heart Failure with Preserved Ejection Fraction, Heart Failure

    phase 2 small molecule active

    1 trial

  4. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  5. Placebo to match LY3848575

    Eli Lilly Co.

    Neuropathic Pain; Distal Sensory Polyneuropathy

    phase 2 small molecule active

    1 trial

  6. Placebo to match buloxibutid oral capsules, Buloxibutid

    Lacuna Pharma Pty Ltd

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  7. Placebo transplantation

    Chinese Academy of Sciences

    Primary Ovarian Insufficiency

    phase 2 mab active

    1 trial

  8. Placebo vials contain 4.5 ml of storage solution only (2.5 ml albumin 20%, 1.1 ml normal saline solution, 0.45 ml Citrate dextrose solution, 0.45 ml Dimethyl sulfoxide). Placebo and MSC vials are indistinguishable in appearance after thawing. There are no observable differences between treatments that could potentially compromise the blind., Mesenchymal stromal cells

    Fondazione Telethon ETS

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  9. Placebo, APG777

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  10. Placebo, BFB759

    Blue Earth Diagnostics Ireland Ltd

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  11. Placebo, EP262, -, EP262

    Lacuna Pharma Pty Ltd

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  12. Placebo, GLUCOPHAGE 500 mg tabletki powlekane

    Bial Portela & Companhia S.A.

    idiopathic infertility

    phase 2 small molecule active

    1 trial

  13. Placebo, Vacuna Phleum pratense 3000 TBU/ml, Vacuna Phleum pratense 1000 TBU/ml, Test de provocación nasal Phleum pratense, Vacuna Phleum pratense 6000 TBU/ml

    Lacuna Pharma Pty Ltd

    Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy

    phase 2 small molecule active

    1 trial

  14. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan Pharma International

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  15. Placebos

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 2 small molecule completed

    1 trial

  16. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  17. Ponsegromab (PF-06946860), Placebo for ponsegromab (pf-06946860) solution for injection

    Pfizer Australia Pty Ltd

    Heart failure

    phase 2 small molecule active

    1 trial

  18. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  19. Povorcitinib, Placebo, Povorcitinib, Povorcitinib

    Incyte

    Treatment of patients with inadequately controlled moderate to severe asthma

    phase 2 small molecule active

    1 trial

  20. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  21. Prednisolon 5 mg JENAPHARM, SPI-62_DF2, Capsule, hard for oral use as placebo for prednisolone., Film-coated tablet for oral use as placebo for Clofutriben (SPI-62)., SPI-62_DF1

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica (PMR)

    phase 2 small molecule active

    1 trial

  22. Prograf 5 mg hard capsules, Prograf 5 mg/ml concentrate for solution for infusion, AT-1501 190 mg Vial, Prograf 0.5 mg hard capsules, Prograf 1 mg hard capsules

    Eledon Pharmaceuticals

    Prophylaxis of Renal Allograft Rejection

    phase 2 small molecule active

    1 trial

  23. Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  24. QBW251

    Novartis Pharmaceuticals

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources